Clovis Oncology Announces Proposed Offering of Common Stock

Monday, 19 June 2017  (3 days ago)
BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $250 million. All shares of the common stock to be sold in the offering will be offered by Clovis Oncology. Clovis Oncology intends to use the net proceeds of the offering for general corporate purposes, including sales and marketing expenses associated with Rubraca® (rucaparib) in th

Recent related news

CARMEL, IN--(Marketwired - Jun 21, 2017) - Determine, Inc. (NASDAQ: DTRM), a pioneering leader in global Source-to-Pay and Enterprise Contract Lifecycle...
2 days ago • Marketwired
BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock
1 day ago • Business Wire
One day after announcing good results of a trial of its ovarian cancer drug rucaparib, Clovis Oncology Inc. said it's commencing a $250 million public offering...
3 days ago • bizjournals
BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology’s Rucaparib Significantly Improved Progression-Free Survival in Phase 3 ARIEL3 Maintenance Study
4 days ago • Business Wire
MEMPHIS, Tenn.--(BUSINESS WIRE)--Jernigan Capital, Inc. (NYSE: JCAP) (the "Company") today announced that it has priced an underwritten public offering of...
14 hours ago • Business Wire
HICKSVILLE, NY--(Marketwired - Jun 15, 2017) - Long Island Iced Tea Corp. (NASDAQ: LTEA) (the "Company"), a growth-oriented company focused on the ready-to-drink...
1 week ago • Marketwired

You might like